• Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

A monoclonal antibody against IL13 reduced histologic and endoscopic features of eosinophilic esophagitis (EoE) in a placebo-controlled phase 2 trial, researchers report in the February issue of Gastroenterology. The antibody, called RPC4046, was well tolerated. EoE is a chronic, immune-mediated disease of the esophagus characterized by eosinophil-mediated mucosal inflammation and

Read more

Identification of Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses

Human monoclonal antibodies able to neutralize live human norovirus GII.4 Sydney 2012—the predominant strain responsible for recent outbreaks—are reported in the December issue of Gastroenterology. Researchers analyzed these antibodies and identified the neutralizing epitopes, providing insight into the human immune response to this deadly virus. Human noroviruses are the major

Read more

Podcast: Efficacy of Vedolizumab in Patients with Moderately to Severely Active Crohn’s disease

Listen to Bruce Sands discuss his article in the September issue of Gastroenterology discussing results from placebo-controlled, phase 3 double-blind trial of the efficacy of vedolizumab  in patients with moderately to severely active Crohn’s disease, including those for whom previous anti-TNF treatment had failed. Sands et al. report that vedolizumab, an antibody against the integrin α4β7, is no more effective

Read more